Colleen Badgley

Colleen represents emerging high-growth companies throughout their life cycle, with a focus on all aspects of emerging company development – including corporate formation, venture capital financings, corporate spinouts and restructurings, and mergers & acquisitions. She also has experience representing public companies and investment banks in public offerings, as well as advising on private placements of equity and debt securities. Colleen is counsel to companies and their investors in a broad range of industries, with a focus on life sciences and technology.

Colleen’s private company clients have included Archon Biosciences, Arzeda, Bonum Therapeutics, Donuts (acquired by Abry Partners), Artemis Health (acquired by Nomi Health), Good Therapeutics (acquired by Roche), HDT Bio, Instacart, LiveStories (doing business as FORWARD), Lumen Bioscience, Myosana Therapeutics, New Engen (acquired by Insignia Capital), Parse Biosciences, Petra Pharma, Polyarc, PvP Biologics (acquired by Takeda), Revalesio, Syndio, Talking Rain, Tasso and Vilya. Her public company clients have included Accolade, Alder Biopharmaceuticals (acquired by Lundbeck), Bolt Biotherapeutics, Etsy and Instructure (acquired by Thoma Bravo). Venture capital firms and investment banks Colleen has represented include Barclays Capital, Cowen and Company, Decheng Capital, Founders’ Co-op, General Catalyst, Goldman Sachs, Jefferies, Lobby Capital, Madrona Venture Group, Redpoint Ventures and Vulcan Capital.

Colleen’s recent representative transactions include advising:

• Accolade in its $221 million secondary public offering Bolt Biotherapeutics in its $264 million initial public offering
• Bonum Therapeutics in its spinout from Good Therapeutics
• Bonum Therapeutics in its $93 million Series A financing
• Form Bio in its $30 million Series A financing
• Good Therapeutics in its sale to Roche
• Kimia Therapeutics in its spinout from Carmot Therapeutics
• Parse Biosciences in its $41.5 million Series B financing
• Petra Pharma in its sale to Eli Lilly
• Polyarc in its $9 million Series B financing
• Syndio in its $17 million Series B financing
• Vilya in its $50 million Series A financing

While at the University of Michigan Law School, Colleen served as an international fellow at the World Intellectual Property Organization in Geneva, Switzerland, and was a member of the Zell Entrepreneurship Clinic.